Latest Conference Coverage

Gauging MS Disease Activity Through Octave’s MSDA Test: Taylor Gonyou, DO

The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on the clinical utility and advantages of a multi-protein test that assesses multiple sclerosis disease activity. [WATCH TIME: 3 minutes]

Glatiramer Acetate Depot Injection Shows T1 and T2 Lesion Reduction in Relapsing MS

Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.

Combination Treatment Approach to Fatigue in MS Nets Benefits

Study results suggest that selected interventions should be based on phenotypic differences and treatment goals.

Disability Progression Risk Lowered in Diverse Patients With Relapsing MS on Ocrelizumab

Non-Hispanic Black and Hispanic or Latino individuals on ocrelizumab did not demonstrate significantly greater risk on 24-week confirmed disability progression relative to non-Hispanic Whites.

High Proportion of Patients Maintained No Evidence of Disease Activity With Ublituximab

Majority of patients with relapsing multiple sclerosis demonstrated achieving and maintaining no evidence disease activity after being treated with ublituximab.

NeuroVoices: Shazam Hussain, MD, FRCP, FAHA, on Weighing Direct to Angio Approaches for Mobile Stroke Units

The director of Cleveland Clinic’s Cerebrovascular Center provided clinical perspective on the treatment decisions mobile stroke units face, and whether directly transferring patients to angiography suite is necessary.

ACTRIMS 2023: What to Expect From the Annual Forum

Daniel Ontaneda, MD, program committee vice-chair of ACTRIMS, provided insight on the notable sessions and themes clinicians should pay attention to at this year’s forum, which takes place February 23-25, in San Diego, California.

Recapping Research From 2023 International Stroke Conference

As a recap from ISC 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates and expert insights.

Expanding the Window to Use Mechanical Thrombectomy, Treat Ischemic Stroke: Gabor Toth, MD

The vascular and interventional neurologist at Cleveland Clinic provided insight on a study presented at the 2023 International Stroke Conference that observed the clinical effectiveness of mechanical thrombectomy beyond 24 hours. [WATCH TIME: 6 minutes]

Closing Remarks, Research Themes in Stroke From ISC 2023: Tudor Jovin, MD

The medical director of the Cooper Neurological Institute spoke at the 2023 International Stroke Conference about notable research themes from the meeting. [WATCH TIME: 10 minutes]

Advantages to Directly Transferring Stroke Treatment to Angiography: Shazam Hussain, MD, FRCP, FAHA

The director of Cleveland Clinic’s Cerebrovascular Center discussed the decisions mobile stroke units face and why opting for direct transfer to angiography is meant for certain scenarios. [WATCH TIME: 3 minutes]

Understanding Nuances of Mobile Stroke Units and When to Transfer Directly to Angiography: Shazam Hussain, MD, FRCP, FAHA

The director of Cleveland Clinic’s Cerebrovascular Center provided perspective on a new study presented at the International Stroke Conference on experiences of poststroke patients taken directly to angiography suite. [WATCH TIME: 3 minutes]

Neuroprotective Effects of ApTOLL, TLR4 Receptor Angatonists to Treat Ischemic Stroke

Investigators Macarena Hernandez, PhD, and Marc Ribo, MD, provided commentary on positive phase 2a findings assessing ApTOLL in combination with EVT in patients with ischemic stroke.

Blood Pressure Medications Not Safe or Effective in Lowering Top Number of BP Reading After Endovascular Stroke Treatment

Blood pressure medications may not be safe or effective to use for lowering systolic blood pressure following endovascular treatment for acute ischemic stroke.

Stroke Prevention and Atrial Fibrillation Management, Thoughts From STROKE-AF Study: Lee Shwamm, MD

The professor of neurology at Harvard Medical School spoke at the 2023 ISC Conference about highlights from the STROKE-AF study after a 3-year follow-up. [WATCH TIME: 5 minutes]

Direct Transfer to Angiography Following Mobile Stroke Unit Leads to Less Successful Recanalization, Increased Mortality

In comparison with those who underwent additional imaging, patients with large vessel occlusion who directly went to angiography suite had higher mortality, but with no difference in functional outcome.

Combination of Higher Dose ApTOLL and EVT Reduces Mortality and Disability in Ischemic Stroke

At the conclusion of the trial, treatment with 0.2 mg/kg of ApTOLL with EVT resulted in reduced brain edema and hemorrhagic transformation, as well as fewer deaths than placebo and 0.05 mg groups.

3-Year Follow-Up of STROKE-AF Demonstrates Stroke Risk Increase With Atrial Fibrillation

Patients with noncardioembolic ischemic stroke do not typically monitor post-stroke longterm to detect atrial fibrillation although findings from a trial follow-up suggest otherwise.

NeuroVoices: Shumei Man, MD, on How Collaboration Between Hospitals Reduces Readmission for Stroke

The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.

Future Plans for ALZ-801 in Homo- and Heterozygous Populations: Susan Abushakra, MD

The chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]

Intellectual and Electrophysiological Disturbances in the Definition of ‘Seizure’: Michael Sperling, MD

Paroxysmal Abnormalities in the Brain and Defining the ‘Seizure’: Michael Sperling, MD

Weighing Epilepsy Surgery as a Potential Treatment Option for Patients: Scott Perry, MD

Building Trust in the Epilepsy Clinician-Patient Relationship: Elizabeth Felton, MD, PhD

The assistant professor in the Department of Neurology at the University of Wisconsin spoke about healthcare providers establishing trust with their patients and improving health equity. [WATCH TIME: 3 minutes]

Post-Stroke Seizure Predictive Models, SeLECT Model: Carolina Ferreira Atuesta, MD, MSc

The scientific researcher and clinical manager, Icahn School of Medicine at Mount Sinai, spoke about the clinical models used to predict seizures in poststroke patients. [WATCH TIME: 4 minutes]

Influence of Antiepileptic Medications on Seizure Frequency in Insomnia: Milena Pavlova, MD

At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about seizure frequency and insomnia. [WATCH TIME: 2 minutes]

Poststroke Epilepsy Management With Antiseizure Medication: Carolina Ferreira Atuesta, MD, MSc

At the 2022 AES Conference, the scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai talked on seizure management with medication in poststroke patients. [WATCH TIME: 3 minutes]

Understanding ALZ-801’s Impact on Alzheimer Pathologies, Brain Atrophy

Susan Abushakra, MD, chief medical officer at Alzheon, provided insight on findings from a phase 2 study in which ALZ-801 showed beneficial effects on cognition, Aß 42/40, and brain atrophy.

Worse Clinical Outcomes, Higher Mortality Rates, and Shorter Lifespans in Epilepsy and Dementia: Ifrah Zawar, MD

The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]

Poststroke Epilepsy and Cerebrovascular Disease: Carolina Ferreira Atuesta, MD, MSc

The scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai, spoke about a talk given at the 2022 AES conference on seizures after ischemic. [WATCH TIME: 5 minutes]